Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Camsirubicin - Monopar Therapeutics

Drug Profile

Camsirubicin - Monopar Therapeutics

Alternative Names: 5-imino-13-deoxy-doxorubicin HCl; CNDO-101; GPX-150; MNPR-201

Latest Information Update: 30 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gem Pharmaceuticals
  • Developer Monopar Therapeutics
  • Class Antineoplastics; Antipsoriatics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Soft tissue sarcoma
  • Discontinued Psoriasis; Solid tumours

Most Recent Events

  • 13 May 2024 Monopar Therapeutics terminates a phase I trial in Soft tissue sarcoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) due to lack of timely enrollment (NCT05043649)
  • 08 Aug 2023 Efficacy and adverse events data from phase-Ib trial in Soft tissue sarcoma released by Monopar Therapeutics
  • 01 Jun 2023 Updated efficacy data from a phase I trial in Soft tissue sarcoma released by Monopar Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top